Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism

Bibliography

• Reyes AJ, Leary WP, Crippa G, et al. The aldosterone antagonist and facultative diuretic eplerenone: a critical review. Eur J Intern Med 2005;16:3-11
   PubMedGoogle Scholar
• Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001;19:353-61
   PubMed Web of Science ®Google Scholar
• Nadar S, Lip GY, Beevers DG. Primary hyperaldosteronism. Ann Clin Biochem 2003;40:439-52
   PubMedGoogle Scholar
• Young WF: Primary aldosteronism. renaissance of a syndrome. Clin Endocrinol (Oxf) 2007;66:607-18
   PubMed Web of Science ®Google Scholar
• Ménard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004;217:45-52
   PubMed Web of Science ®Google Scholar
• Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004;217:27-31
   PubMed Web of Science ®Google Scholar
• White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16
   PubMed Web of Science ®Google Scholar
• White WB, Carr AA, Krause S, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003;92:38-42
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992;1:113-9
   PubMedGoogle Scholar
• Gennari FJ. Hypokalemia. N Engl J Med 1998;339:451-8
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Tziomalos K, Kakafika A, et al. Paralysis as first manifestation of primary aldosteronism. Nephrol Dial Transplant 2004;19:2418-9
   PubMedGoogle Scholar
• Janmohamed S, Bouloux PM. The pharmacological treatment of primary aldosteronism. Expert Opin Pharmacother 2006;7:563-73
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Tziomalos K, Kakafika A, et al. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant 2007;22:293
   PubMedGoogle Scholar
• Schirpenbach C, Reincke M. Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nat Clin Pract Endocrinol Metab 2007;3:220-7
   PubMedGoogle Scholar
• Gordon RD, Ziesak MD, Tunny TJ, et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993;20:296-8
   PubMed Web of Science ®Google Scholar
• Fardella CE, Mosso L, Gómez-Sánchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000;85:1863-7
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000;54(Suppl 1):83s-85s
   Google Scholar
• Denolle T, Chatellier G, Julien J, et al. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 1993;6:907-13
   PubMed Web of Science ®Google Scholar
• Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995;13:1801-2
   PubMed Web of Science ®Google Scholar
• Takeda R, Matsubara T, Miyamori I, et al. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 1995;18:370-3
   PubMedGoogle Scholar
• Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27:1039-45
   PubMed Web of Science ®Google Scholar
• Funder JW. Mineralocorticoid receptors and hypertension. J Steroid Biochem Mol Biol 1995;53:53-5
   PubMedGoogle Scholar
• Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-14
   PubMed Web of Science ®Google Scholar
• Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 2002;970:89-100
   PubMed Web of Science ®Google Scholar
• Weber KT. Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone. J Lab Clin Med 2003;142:71-82
   PubMed Web of Science ®Google Scholar
• Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-10
   PubMed Web of Science ®Google Scholar
• Young MJ, Moussa L, Dilley R, Funder JW. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 2003;144:1121-5
   PubMed Web of Science ®Google Scholar
• Iglarz M, Touyz RM, Viel EC, et al. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the rennin-angiotension system. Am J Hypertens 2004;17:597-603
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81
   PubMed Web of Science ®Google Scholar
• Beswick RA, Zhang H, Marable D, et al. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001;37:781-6
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Tziomalos K, Dona K, et al. Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient. QJM 2005;98:913-5
   PubMedGoogle Scholar
• Rossi GP, Sacchetto A, Chiesura-Corona M, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001;86:1083-90
   PubMed Web of Science ®Google Scholar
• Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004;136:1227-35
   PubMed Web of Science ®Google Scholar
• Nwariaku FE, Miller BS, Auchus R, et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006;141:497-502
   PubMedGoogle Scholar
• Gordon RD, Stowasser M, Rutherford JC. Primary aldosteronism: are we diagnosing and operating on too few patients? World J Surg 2001;25:941-7
   PubMedGoogle Scholar
• Brown JJ, Davies DL, Ferriss JB, et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. BMJ 1972;2:729-34
   PubMed Web of Science ®Google Scholar
• Ferriss JB, Beevers DG, Boddy K, et al. The treatment of low-renin (‘primary’) hyperaldosteronism. Am Heart J 1978;96:97-109
   PubMed Web of Science ®Google Scholar
• Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999;131:105-8
   PubMedGoogle Scholar